This product is an oral broad-spectrum second-generation cephalosporin. Its antibacterial mechanism is to inhibit the synthesis of bacterial cell walls by binding to bacterial proteins. Cefuroxime has a wide range of antibacterial activity against pathogens and is stable against many β-lactamases, especially plasmid-mediated enzymes commonly found in Enterobacteriaceae.

This product is an oral broad-spectrum second-generation cephalosporin. Its antibacterial mechanism is to inhibit the synthesis of bacterial cell walls by binding to bacterial proteins. Cefuroxime has a wide range of antibacterial activity against pathogens and is stable against many β-lactamases, especially plasmid-mediated enzymes commonly found in Enterobacteriaceae.

The second generation cephalosporin antibiotics have similar or slightly worse antibacterial activity against Gram-positive cocci than the first generation cephalosporins, but are quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, and other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity against Staphylococcus aureus is worse than that of cefazolin, and 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, Serratia is mostly resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. The mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

The second generation cephalosporin antibiotics have similar or slightly inferior antibacterial activity against Gram-positive cocci as the first generation cephalosporins, but are quite stable against β-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, and other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity against Staphylococcus aureus is worse than that of cefazolin, and 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, Serratia is mostly resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

It achieves bactericidal effect by inhibiting the synthesis of bacterial cell wall. It has bactericidal effect on a wide range of common clinical bacteria and can resist hydrolysis by multiple beta-lactamases. Bacteria sensitive to this product include Gram-positive bacteria, Gram-negative bacteria and some anaerobic bacteria.